Einav Nili Gal-Yam
Overview
Explore the profile of Einav Nili Gal-Yam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ben-Shmuel A, Gruper Y, Halperin C, Levi-Galibov O, Rosenberg-Fogler H, Barki D, et al.
Cancer Discov
. 2025 Mar;
PMID: 40052789
Cancer-associated fibroblasts (CAFs) are abundant components of the breast tumor microenvironment and major contributors to immune-modulation. CAFs regulate the activity of many immune cells including T-cells, macrophages and dendritic cells,...
2.
Bernstein-Molho R, Haisraely O, Galper S, Abu-Shhada N, Nili Gal-Yam E, Menes T, et al.
Breast Cancer Res Treat
. 2025 Mar;
PMID: 40042736
Purpose: Our previous data showed that carriers of germline BRCA1/2 pathogenic variants (PV) with breast cancer (BC) treated with mastectomy without post-mastectomy radiation therapy (PMRT) had higher rates of loco-regional...
3.
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al.
JAMA
. 2025 Jan;
PMID: 39883436
Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic...
4.
Bernstein-Molho R, Abu-Shehada N, Nili Gal-Yam E, Zippel D, Menes T, Sklair-Levy M, et al.
Pract Radiat Oncol
. 2024 Sep;
14(5):435-442.
PMID: 39218527
Purpose: Several international groups have published guidelines to identify low-risk breast cancer (BC) patients who are eligible for partial breast irradiation (PBI). These include the American Society for Radiation Oncology...
5.
Nili Gal-Yam E, Levanon K
JCO Precis Oncol
. 2023 Dec;
7:e2300097.
PMID: 38085049
No abstract available.
6.
Halpern N, Boursi B, Shacham-Shmueli E, Nili Gal-Yam E, Margalit O, Golan T, et al.
Oncol Ther
. 2023 Oct;
11(4):513-519.
PMID: 37864026
Introduction: It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume systemic anti-neoplastic treatment in patients with cancer. We assessed the...
7.
Shachar S, Leviov M, Yerushalmi R, Drumea K, Tokar M, Soussan-Gutman L, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):79.
PMID: 37775723
Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second...
8.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...
9.
Rein M, Dadiani M, Godneva A, Bakalenik-Gavry M, Morzaev-Sulzbach D, Vachnish Y, et al.
BMJ Open
. 2022 Nov;
12(11):e062498.
PMID: 36410828
Introduction: Breast cancer survivors treated with adjuvant endocrine therapy commonly experience weight gain, which has been associated with low adherence to therapy and worse breast cancer prognosis. We aim to...
10.
Rugo H, Im S, Cardoso F, Cortes J, Curigliano G, Musolino A, et al.
J Clin Oncol
. 2022 Nov;
41(2):198-205.
PMID: 36332179
JCO Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2-positive...